Beigene/Boehringer Biomanufacturing Bond Tests China MAH System
This article was originally published in PharmAsia News
Nasdaq-listed BeiGene expects to need more CMO services for its clinical stage biologics following on from a clinical trials manufacturing agreement for a PD-1 antibody with Boehringer Ingelheim China, which marked the first such pilot program under China’s drug marketing authorization holder system. Shanghai is also preparing risk guarantee funds to back the pilot program, in order to promote pharmaceutical innovation.
Register for our free email digests: